"SANKYO" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonDaiichi stops internal development of next-wave ADC as key Datroway readout delayed again - Fierc...
Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again Fierce Biotech
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline - BioSpace
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline BioSpace
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portf...
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo Business Wire
Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance - F...
Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance Fierce Pharma
Daiichi Sankyo (4568 JP): Enhertu Drives 9MFY26 Result; FY Guidance Reiterated - Smartkarma
Daiichi Sankyo (4568 JP): Enhertu Drives 9MFY26 Result; FY Guidance Reiterated Smartkarma
Banking on the long-term potential of oncology drugs: Daiichi Sankyo CFO - MSN
Banking on the long-term potential of oncology drugs: Daiichi Sankyo CFO MSN
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For...
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year simplywall.st
Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial - marke...
Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial marketscreener.com
Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial - TipRanks
Bayer and Daiichi Sankyo Advance New Prostate Cancer Combo in Early-Stage Trial TipRanks
Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress - Morn...
Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress Morningstar
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncolo...
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology PR Newswire
Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic tri...
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program - The Globe and Mail
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program The Globe and Mail
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ - Pharmaceutical Techno...
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ Pharmaceutical Technology
How DATROWAY’s Priority Review in Metastatic TNBC May Impact Daiichi Sankyo Company (TSE:4568) In...
How DATROWAY’s Priority Review in Metastatic TNBC May Impact Daiichi Sankyo Company (TSE:4568) Investors simplywall.st
Daiichi Sankyo tallies $1.9B in planned Enhertu manufacturing investments: Nikkei - Fierce Pharma
Daiichi Sankyo tallies $1.9B in planned Enhertu manufacturing investments: Nikkei Fierce Pharma
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Tr...
Daiichi Sankyo (TSE:4568) Margin Improvement Supports Bullish Growth Narrative In Q3 2026 - simpl...
Daiichi Sankyo (TSE:4568) Margin Improvement Supports Bullish Growth Narrative In Q3 2026 simplywall.st
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference? - Pharma...
What is Daiichi Sankyo’s Strategy for Preparing for the JP Morgan Healthcare Conference? Pharmaceutical Executive
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $...
Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict Fierce Pharma
Daiichi Sankyo Q3 FY2025 slides: Oncology portfolio drives 12.1% revenue growth - Investing.com
Daiichi Sankyo Q3 FY2025 slides: Oncology portfolio drives 12.1% revenue growth Investing.com
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC - BioSpace
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC BioSpace
Daiichi Sankyo Company: Strong oncology sales drove revenue and profit growth, with robust pipeli...
Daiichi Sankyo Company: Strong oncology sales drove revenue and profit growth, with robust pipeline momentum TradingView
Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Moat? - Yah...
Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Moat? Yahoo Finance
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service | Amazon Web Se...
How Daiichi Sankyo modernized drug discovery using AWS Parallel Computing Service | Amazon Web Services Amazon Web Services (AWS)
AstraZeneca, Daiichi Sankyo announce Datroway sBLA granted priority review - TipRanks
AstraZeneca, Daiichi Sankyo announce Datroway sBLA granted priority review TipRanks
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu - Clinical Trials Arena
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu Clinical Trials Arena
General Proximity and Daiichi Sankyo link on oncology - Pharmaceutical Technology
General Proximity and Daiichi Sankyo link on oncology Pharmaceutical Technology
Is It Time To Reconsider Daiichi Sankyo Company (TSE:4568) After Recent Share Price Weakness? - Y...
Is It Time To Reconsider Daiichi Sankyo Company (TSE:4568) After Recent Share Price Weakness? Yahoo Finance
Earnings call transcript: Daiichi Sankyo Q3 2025 earnings beat expectations - Investing.com
Earnings call transcript: Daiichi Sankyo Q3 2025 earnings beat expectations Investing.com
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer - BioSpace
AstraZeneca, Daiichi Sankyo Move Enhertu to First-Line Metastatic Breast Cancer BioSpace
Daiichi Sankyo Company: Oncology-driven revenue and profit growth offset by one-time costs; outlo...
Fierce Pharma Asia—AZ's $15B China investment; Boehringer, Simcere's IBD deal; Daiichi's ADC grow...
Fierce Pharma Asia—AZ's $15B China investment; Boehringer, Simcere's IBD deal; Daiichi's ADC growth push Fierce Pharma
Daiichi Sankyo appoints new head for European research center - The Pharma Letter
Daiichi Sankyo appoints new head for European research center The Pharma Letter
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data - TipRanks
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data TipRanks
AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status - marketscre...
AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status marketscreener.com
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00 - simplywall.st
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00 simplywall.st
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd - BioSpace
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd BioSpace
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. - ...
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next. BioPharma Dive
Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video - Fier...
Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video Fierce Pharma
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe...
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe Business Wire
General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advanc...
Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Advantage? ...
Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Advantage? simplywall.st
Japan's Daiichi Sankyo unveils new Toronto headquarters to accelerate investment and innovation i...
Japan's Daiichi Sankyo unveils new Toronto headquarters to accelerate investment and innovation in oncology BioSpectrum Asia
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? - Yahoo Finance
Is Daiichi Sankyo Now an Opportunity After a 26% Share Price Slide? Yahoo Finance
Daiichi Sankyo’s Vanflyta secures Korean approval for FLT3-ITD–positive AML - koreabiomed.com
Daiichi Sankyo’s Vanflyta secures Korean approval for FLT3-ITD–positive AML koreabiomed.com
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives - Yah...
Daiichi Sankyo (TSE:4568) Earnings Growth Slows to 11.8%, Testing Recent Bullish Narratives Yahoo Finance
Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable...
Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S marketscreener.com
Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Bioma...
Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Biomarkers and Translational Oncology Pharmaceutical Executive
Stock Pitch: Daiichi Sankyo (TSE: 4568) - Morningstar Canada
Stock Pitch: Daiichi Sankyo (TSE: 4568) Morningstar Canada
Lunit links up with Daiichi Sankyo in oncology - The Pharma Letter
Lunit links up with Daiichi Sankyo in oncology The Pharma Letter
ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer - Clinical Tri...
ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer Clinical Trials Arena
Daiichi Sankyo launches its STING operation against cancer - pharmaphorum
Daiichi Sankyo launches its STING operation against cancer pharmaphorum
Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer ...
Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer BioPharm International
New Indication Alert: AZ/Daiichi Sankyo’s Enhertu® Approved in China for HER2 Positive Metastatic...
Daiichi Sankyo : Notice on the Determined Basic Policy for Absorption-type Merger of Daiichi Sank...
Is It Time To Reconsider Daiichi Sankyo Company (TSE:4568) After Recent Share Price Weakness? - s...
Is It Time To Reconsider Daiichi Sankyo Company (TSE:4568) After Recent Share Price Weakness? simplywall.st
Daiichi Sankyo's Nine-Month Profit Rises 4% - marketscreener.com
Daiichi Sankyo's Nine-Month Profit Rises 4% marketscreener.com
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates ...
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 - Yahoo Finance
What Recent Oncology Deal Means for Daiichi Sankyo Shares in 2025 Yahoo Finance
Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line tr...
Daiichi Sankyo Establishes Third Research Institute in San Diego - Business Wire
Daiichi Sankyo Establishes Third Research Institute in San Diego Business Wire
4568.T Daiichi Sankyo (JPX) earnings 30 Jan 2026: Key metrics to watch - Meyka
4568.T Daiichi Sankyo (JPX) earnings 30 Jan 2026: Key metrics to watch Meyka
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...
Lunit partners with Daiichi Sankyo to accelerate novel cancer drug development using AI - koreabi...
Lunit partners with Daiichi Sankyo to accelerate novel cancer drug development using AI koreabiomed.com
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics - Pharmafile
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics Pharmafile
Is Daiichi Sankyo (TSE:4568) Undervalued After Recent Share Price Weakness? A Fresh Look at Its 2...
Is Daiichi Sankyo (TSE:4568) Undervalued After Recent Share Price Weakness? A Fresh Look at Its 2028 Outlook Yahoo Finance
How Breakthrough ESMO 2025 Oncology Data at Daiichi Sankyo (TSE:4568) Has Changed Its Investment ...
How Breakthrough ESMO 2025 Oncology Data at Daiichi Sankyo (TSE:4568) Has Changed Its Investment Story Yahoo Finance
Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan - BioPharm International
Daiichi Sankyo’s Breast Cancer Treatment, Enhertu, Approved in Japan BioPharm International
Daiichi Sankyo is leveraging Azure OpenAI Service to develop generative AI and foster an AI-frien...
Daiichi Sankyo (TSE:4568): Exploring Valuation as Investor Attention Grows - Yahoo Finance
Daiichi Sankyo (TSE:4568): Exploring Valuation as Investor Attention Grows Yahoo Finance
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lower...
Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades - Bloomberg.com
Japan’s Daiichi Sankyo Shares Drop After Discounted Block Trades Bloomberg.com
Will Sankyo’s (TSE:6417) Anime Strategies Redefine Its Competitive Edge in the Gaming Market? - Y...
Will Sankyo’s (TSE:6417) Anime Strategies Redefine Its Competitive Edge in the Gaming Market? Yahoo Finance
Armand Cognetta: General Proximity Will Collaborate with Daiichi Sankyo US - Oncodaily
Armand Cognetta: General Proximity Will Collaborate with Daiichi Sankyo US Oncodaily
Daiichi Sankyo’s Dr Michael Zaiac on moving beyond ‘sick care’ - European Medical Journal
Daiichi Sankyo’s Dr Michael Zaiac on moving beyond ‘sick care’ European Medical Journal
Lunit, Daiichi Sankyo to partner on AI biomarker, oncology research - AuntMinnie
Lunit, Daiichi Sankyo to partner on AI biomarker, oncology research AuntMinnie
AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy ...
AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy Yahoo Finance
Daiichi Sankyo (OTCMKTS:DSNKY) Reaches New 52-Week Low - Here's What Happened - MarketBeat
Daiichi Sankyo (OTCMKTS:DSNKY) Reaches New 52-Week Low - Here's What Happened MarketBeat
Daiichi Sankyo (TSE:4568) Earnings Growth Reinforces Bullish Narratives on Consistent Outperforma...
Daiichi Sankyo (TSE:4568) Earnings Growth Reinforces Bullish Narratives on Consistent Outperformance and Valuation simplywall.st
Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to A...
Daiichi Sankyo's Nine-Month Profit Rises 4% - 富途牛牛
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Ce...
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe Yahoo Finance
Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation - Yahoo Finance
Merck (MRK) And Daiichi Sankyo's R-DXd Receives FDA Breakthrough Therapy Designation Yahoo Finance
Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for...
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a Ne...
AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer - MedCity News
AstraZeneca, Daiichi Sankyo ADC Enhertu Moves Up to First-Line Use in Breast Cancer MedCity News
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute betwe...
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen Business Wire
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo - Business Wire
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo Business Wire
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enher...
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab Applied Clinical Trials
Daiichi Sankyo Unveils New Toronto Headquarters To Accelerate Investment And Innovation In Oncolo...
Daiichi Sankyo Unveils New Toronto Headquarters To Accelerate Investment And Innovation In Oncology TradingView
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA - Pharmaceutical Technology
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA Pharmaceutical Technology
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings - B...
Merck, Daiichi Sankyo Pull Lung Cancer Filing for ADC, Citing Underwhelming Survival Findings BioSpace
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ...
Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 O...
Daiichi Sankyo and Merck Pull Back Patritumab Deruxtecan BLA Based on Phase III HERTHENA-Lung02 Outcomes Applied Clinical Trials
Datroway demonstrated statistically significant and clinically meaningful improvement in overall ...
Lunit partners with Daiichi Sankyo to advance AI-driven oncology research - BioSpectrum Asia
Lunit partners with Daiichi Sankyo to advance AI-driven oncology research BioSpectrum Asia
Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI - HIT Consultant
Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI HIT Consultant
Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen - Endpoints News
Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen Endpoints News
Immuto Scientific announces financing, Daiichi Sankyo collab - BioWorld MedTech
Immuto Scientific announces financing, Daiichi Sankyo collab BioWorld MedTech